ADAMTS-7 Metalloprotease Peptide Vaccine for Anti-Atherosclerosis - Beijing Kimway
Summary
The USPTO granted patent US12599654B2 to Beijing Kimway Biotech Co. Ltd. covering immunogenic peptide fragments of metalloprotease ADAMTS-7 and their use in anti-atherosclerosis vaccines. The patent, granted April 14, 2026 with an original filing date of August 20, 2020, includes 3 claims covering short peptide sequences (SEQ ID NO: 1-4) and vaccine compositions designed to inhibit vascular restenosis and atherosclerosis in mouse models.
What changed
The USPTO granted patent US12599654B2 to Beijing Kimway Biotech Co. Ltd. covering immunogenic peptide fragments of metalloprotease ADAMTS-7 and their applications in anti-atherosclerosis vaccines and related diseases. The patent protects four short peptide sequences and conjugate/vaccine compositions containing those sequences, with demonstrated efficacy in inhibiting intimal neogenesis in vascular restenosis mouse models and reducing atherosclerosis occurrence in high-fat-fed mice.
Affected parties including biotechnology manufacturers, pharmaceutical companies, and researchers developing atherosclerosis or vascular restenosis treatments should monitor this patent for potential licensing requirements or freedom-to-operate considerations. The patent provides Beijing Kimway Biotech with exclusive rights to ADAMTS-7 peptide vaccine technology in the United States through its filing under CPC classifications C07K 14/8146, C07K 7/06, and A61K 39/001158.
What to do next
- Monitor for updates
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Immunogenic peptide fragments of metalloprotease ADAMTS-7 and uses thereof in anti-atherosclerosis and related diseases
Grant US12599654B2 Kind: B2 Apr 14, 2026
Assignee
BEIJING KIMWAY BIOTECH CO. LTD
Inventors
Wei Kong, Yi Fu, Jingang Zheng, Zihan Ma, Yuhua Liao, Xiao Chen, Chenfeng Mao
Abstract
Immunogenic peptide fragments of metalloprotease ADAMTS-7 including a first short peptide, which is any one of the followings: a short peptide having the amino acid sequence shown in SEQ ID NO: 1 in the sequence listing; a short peptide having the amino acid sequence shown in SEQ ID NO: 2 in the sequence listing; a short peptide having the amino acid sequence shown in SEQ ID NO: 3 in the sequence listing; a short peptide having the amino acid sequence shown in SEQ ID NO: 4 in the sequence listing. The description includes uses of conjugates containing the above short peptides and vaccines containing the conjugates. The vaccines containing the short peptides can remarkably inhibit the intimal neogenesis in the vascular restenosis mouse models and the occurrence of atherosclerosis in high-fat-fed mice, and can be used for the prevention or treatment of atherosclerosis and/or vascular restenosis.
CPC Classifications
C07K 14/8146 C07K 7/06 A61K 39/001158 C12Y 304/24
Filing Date
2020-08-20
Application No.
17642837
Claims
3
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.